AVROBIO

90 articles with AVROBIO

• AVROBIO to Present at the JMP Securities Life Sciences Conference

  6/10/2021

  AVROBIO, Inc. today announced Geoff MacKay, president and CEO of AVROBIO, will present at the JMP Securities Life Sciences Conference at 10:30 a.m. ET on Thursday, June 17, 2021.

• AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021

  6/4/2021

  AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to an aggregate of 8,250 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement Plan.

• AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update

  5/13/2021

  Held meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for AVR-RD-01 for Fabry disease Dosing completion in ongoing FAB-GT Phase 2 trial reaches 50%, with three additional patients dosed in three months

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2021

  5/6/2021

  AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 163,500 shares of the company’s common stock to five new employees as inducement awards, consisting of 30,500 shares granted under the company’s 2019 Inducement Plan and 133,000 shares granted under the company’s 2020 Inducement Plan.

• AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

  5/3/2021

  AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease Anticipates initiating registration trial with kidney biopsy endpoint in mid-2022 to support potential full approval of AVR-RD-01 as first-line therapy, subject to FDA discussion and agreement Two additional patients dosed in last two months in ongoing FAB-GT Phase 2 trial; plan to enroll a total of up to 14 participants

• AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting

  4/27/2021

  AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that two oral presentations and two posters featuring data from its pipeline of lysosomal disorder gene therapy programs will be shared at the 24th virtual Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), May 11-14, 2021.

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 06, 2021

  4/6/2021

  AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 140,000 shares of the company’s common stock to 10 new employees as inducement awards under the company’s 2019 Inducement Plan.

• AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

  3/18/2021

  100% kidney substrate reduction at 12 months post-gene therapy in the first patient dosed with the plato ® gene therapy platform in FAB-GT 1 trial for Fabry disease One new patient dosed and three new patients enrolled in Fabry disease clinical trial since January 2021 Orphan drug designation received from European Commission for AVR-RD-04 for cystinosis and AVR-RD-01 for Fabry disease

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 05, 2021

  3/5/2021

  AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 61,500 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan.

• AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis

  3/1/2021

  AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis.

• AVROBIO to Present at Three Upcoming Investor Conferences in March

  2/25/2021

  AVROBIO to Present at Three Upcoming Investor Conferences in March

• 

  Clinical Catch-Up: February 8-12

  2/15/2021

  It was a busy week for clinical trial announcements and news. Here’s a look.

• AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial

  2/8/2021

  AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato ® Gene Therapy Platform in Fabry Disease Phase 2 Trial Consistent with the 87% reduction in the first evaluable kidney biopsy, there is complete clearance of Gb3 inclusions in second evaluable kidney biopsy in Fabry disease Phase 2 trial

• 

  Avrobio Gene Therapy Shows Early Promise in Fabry, Other Rare Lysosomal Diseases

  2/8/2021

  Shares of Avrobio were up nearly 20% in premarket trading after the company posted positive clinical data from its gene therapy trials in three different rare lysomal diseases, Fabry, Gaucher type 1 and cystinosis.

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 05, 2021

  2/5/2021

  AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to 10,250 shares of the company’s common stock to a new employee as an inducement award under the company’s 2019 Inducement Plan.

• AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium™ 2021

  2/1/2021

  AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17 th Annual WORLD Symposium ™ 2021 Analyst and investor event scheduled for Monday, Feb. 8 at 8:00 a.m. ET Four platform presentations and two posters on the company’s clinical and preclinical programs for lysosomal disorders are scheduled throughout 17 th annual WORLDSymposium™

• AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit

  1/22/2021

  AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit at 11:30 a.m. ET on Friday, Jan. 29, 2021.

• 

  BioSpace Movers & Shakers, Jan. 22

  1/22/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• AVROBIO to Present at the ICR Conference 2021

  1/8/2021

  AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present virtually at the ICR Conference 2021 at 11:30 a.m. ET on Thursday, Jan. 14, 2021. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors & Media section

• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 07, 2021

  1/7/2021

  AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 85,250 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.